Fig. 2

Differentially Methylated CG Sites at different stages of breast cancer patients. a Heat map of hierarchical clustering of nine healthy individuals and 28 breast cancer patients by beta values of 10,859 differentially methylated CGs (p < 0.05). b Heat map of hierarchical clustering of 1902 differentially methylated CGs (p < 0.05) in early stages of breast cancer, in healthy individuals and early and late stages of breast cancer patients. c Heat map of hierarchical clustering of nine healthy individuals and 3 and 4 breast cancer stages 9 patients by beta values of top 2239 differentially methylated CGs (p < 0.01). d Venn diagram showing significant overlap (p = 9.47e-321, hypergeometric) of methylation changes between early (1 and 2) and late (3 and 4) stages. e Venn diagram showing overlap of top 89 CpG whose quantitative level of DNA methylation correlate with progression with differentially methylated CpGs in early and late stages of breast cancer. f Red dots indicate 89 the most significant CpG sites (adjusted P value< 0.05, and R > 0.7 or R < 0.7), whose DNA methylation level correlate with breast cancer progression. Delta beta indicates the differences of DNA methylation between average of stage 4 and normal individuals. Green line separate between 10,772 CpG sites (top) whose DNA methylation level correlate with breast cancer progression and not significantly changed CpGs DNA methylation (bottom)